

# HEXIM1 Regulates 17 $\beta$ -Estradiol/Estrogen Receptor- $\alpha$ -Mediated Expression of Cyclin D1 in Mammary Cells via Modulation of P-TEFb

Ndiya Ogba,<sup>1</sup> Laura J. Chaplin,<sup>1</sup> Yong Qiu Doughman,<sup>3</sup> Koh Fujinaga,<sup>2</sup> and Monica M. Montano<sup>1</sup>

<sup>1</sup>Department of Pharmacology, <sup>2</sup>Division of Infectious Diseases and Department of Molecular Biology and Microbiology, Case Western Reserve University; and <sup>3</sup>Division of Pediatric Cardiology, Department of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, Ohio

## Abstract

Estrogen receptor  $\alpha$  (ER $\alpha$ ) plays a key role in mammary gland development and is implicated in breast cancer through the transcriptional regulation of genes linked to proliferation and apoptosis. We previously reported that hexamethylene bisacetamide inducible protein 1 (HEXIM1) inhibits the activity of ligand-bound ER $\alpha$  and bridges a functional interaction between ER $\alpha$  and positive transcription elongation factor b (P-TEFb). To examine the consequences of a functional HEXIM1-ER $\alpha$ -P-TEFb interaction *in vivo*, we generated MMTV/HEXIM1 mice that exhibit mammary epithelial-specific and doxycycline-inducible expression of HEXIM1. Increased HEXIM1 expression in the mammary gland decreased estrogen-driven ductal morphogenesis and inhibited the expression of cyclin D1 and serine 2 phosphorylated RNA polymerase II (S2P RNAP II). In addition, increased HEXIM1 expression in MCF-7 cells led to a decrease in estrogen-induced cyclin D1 expression, whereas down-regulation of HEXIM1 expression led to an enhancement of estrogen-induced cyclin D1 expression. Studies on the mechanism of HEXIM1 regulation on estrogen action indicated a decrease in estrogen-stimulated recruitment of ER $\alpha$ , P-TEFb, and S2P RNAP II to promoter and coding regions of ER $\alpha$ -responsive genes *pS2* and *CCND1* with increased HEXIM1 expression in MCF-7 cells. Notably, increased HEXIM1 expression decreased only estrogen-induced P-TEFb activity. Whereas there have been previous reports on HEXIM1 inhibition of P-TEFb activity, our studies add a new dimension by showing that E<sub>2</sub>/ER is an important regulator of the HEXIM1/P-TEFb functional unit in breast cells. Together, these studies provide novel insight into the role of HEXIM1 and ER $\alpha$  in mammary epithelial cell function. [Cancer Res 2008;68(17):7015–24]

## Introduction

Mammary gland morphogenesis and development requires input from several genetic and epigenetic pathways regulated by hormones and growth factors including estrogens (1, 2). Estrogens mediate their actions through estrogen receptors (ER), ER $\alpha$  and ER $\beta$ , nuclear steroid receptors that classically regulate transcrip-

tion either by directly binding to estrogen response elements of target genes (3–5) or indirectly via protein-protein interactions with other transcription factors like SP1 or activator protein 1 (AP-1; ref. 6). In both cases, coregulatory proteins are also recruited to the promoter, and together ERs and these factors elicit changes in mRNA and protein levels of ER target genes and, ultimately, a physiologic response (4–6). Because estrogen signaling controls the balance of growth and apoptosis in normal breast epithelial cells, a disruption of this balance contributes to abnormal cell growth and can lead to tumorigenesis (4, 7). Therefore, it is important to identify and elucidate the mechanism of action of ERs and their coregulators that give better insight into ER-mediated transcriptional regulation (8).

In eukaryotic transcription, the elongation stage is highly regulated and important for the generation of full-length mRNA transcripts (9–11). One of the positive regulators, positive transcription elongation factor b (P-TEFb), has an essential role in RNA polymerase II (RNAP II) transcription elongation (9, 10). In many human cell types, the predominant form of P-TEFb consists of cyclin-dependent kinase 9 (CDK9) and its regulatory partner, cyclin T1 (11). It phosphorylates and thereby inhibits the activity of negative elongation factors, NELF and DSIF (DRB sensitivity inducing factor; ref. 9). It also phosphorylates the COOH-terminal repeat domain (CTD) of the largest subunit of RNAP II (9, 10). The RNAP II CTD consists of multiple repeats of the heptapeptide sequence, YSPTSPS, phosphorylated at serine 5 by general transcription factor TFIIF during initiation and at serine 2 by P-TEFb during elongation (9, 10). These phosphorylation events are crucial for effective transition from an abortive to a productive phase of elongation (11, 12). P-TEFb is essential for productive HIV-1 transcriptional elongation and several studies have shown that various transcription factors bind to and recruit P-TEFb to specific promoters stimulating elongation (12, 13).

In previous studies, we identified an ER $\alpha$ -interacting protein, estrogen down-regulated gene-1 [also known as hexamethylene inducible protein 1 (HEXIM1)], and found that it is an inhibitor of ER $\alpha$  transcription and breast cell growth (14). Additionally, we showed that HEXIM1 expression was lower in human breast tumors when compared with adjacent normal tissue, suggesting a role for HEXIM1 in breast tumorigenesis (14). Concurrent studies identified HEXIM1 as a P-TEFb-interacting factor that also inhibits P-TEFb activity (15, 16). Studies have also shown that HEXIM2, a paralogue of HEXIM1, has the same inhibitory effect on P-TEFb (17, 18). We showed that HEXIM1 modulates a functional interaction between ER $\alpha$  and cyclin T1 in breast epithelial cells and inhibits the recruitment of ligand-bound ER $\alpha$  (E<sub>2</sub>/ER $\alpha$ ) to the *pS2* gene promoter (19). We also found that cyclin T1 seemed to be

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

**Requests for reprints:** Monica M. Montano, Department of Pharmacology, Case Western Reserve University School of Medicine, H.G. Wood Building W307, 2109 Adelbert Road, Cleveland, OH 44106. Phone: 216-368-3378; Fax: 216-368-3395; E-mail: mxm126@po.cwru.edu.

©2008 American Association for Cancer Research.  
doi:10.1158/0008-5472.CAN-08-0814

necessary for  $E_2$  induction of cyclin D1 protein expression (19). Cyclin D1 (CCND1) is a D-type cyclin that regulates G<sub>1</sub>-S cell cycle progression during cell proliferation (20). CCND1 is also  $E_2$ /ER $\alpha$  responsive and is thought to play major roles in mammary gland development and breast cancer (1, 21). However, the contribution of  $E_2$ /ER $\alpha$  to HEXIM1 action in breast cells is not well defined. In addition, the precise mechanism by which P-TEFb regulates CCND1 transcription and how this can be linked to mammary gland development and tumorigenesis need to be further defined.

To address these questions, we developed a transgenic mouse model in our laboratory that is doxycycline inducible and selectively expresses HEXIM1 in the mammary gland under the control of the mouse mammary tumor virus long terminal repeat (MMTV-LTR) promoter previously described (22). Using this model, we show that increased HEXIM1 expression decreased  $E_2$ -induced CCND1 and serine 2 phosphorylated (S2P) RNAP II expression in the mouse mammary gland. In addition, increasing HEXIM1 expression inhibits  $E_2$ -induced recruitment of ER $\alpha$ , P-TEFb, and S2P RNAP II to ER-responsive genes, *pS2* and *CCND1*, in MCF-7 cells. Finally, we observed that  $E_2$  stimulates P-TEFb activity and that HEXIM1 inhibits only  $E_2$ -induced, and not basal, P-TEFb activity. These results elucidate the functional consequences of modulating HEXIM1 expression on  $E_2$ /ER $\alpha$ -driven transcription in the mammary gland and its implications for estrogen-dependent breast cancer.

## Materials and Methods

**Materials and antibodies.** 17 $\beta$ -Estradiol ( $E_2$ ) and CDK9 inhibitor 5,6-dichloro-1- $\beta$ -D-ribofuranosylbenzimidazole (DRB) were obtained from Sigma Chemical Co. Commercially available antibodies used for immunoprecipitation and Western blot analysis are described in Supplementary data.

**Transgenic mouse (MMTV/HEXIM1) generation.** MMTV-rtTA mice were generated as described by Gunther and colleagues (22). To generate pTET-HEXIM1 mice, a plasmid construct was made by subcloning the coding sequence of human HEXIM1 gene downstream of the tetracycline-dependent minimal promoter in the pTet-splice transgene construct. After purification, the resulting plasmid was used for pronuclear injection into FVB oocytes (Case Western Reserve University Transgenic and Targeting Facility). To achieve mammary gland-specific expression of HEXIM1 in a doxycycline-dependent manner, pTET-HEXIM1 mice were crossed with the MTB line, which expressed the reverse tetracycline-dependent transcriptional activator (rtTA) under the control of the MMTV-LTR. From these matings the bigenic mice, MMTV/HEXIM1, were created. Transgene expression was induced by adding 2 mg/mL doxycycline to the drinking water. Bigenic mice were identified by screening genomic DNA from tail biopsies for the presence of the transgenes using PCR and verified by Western blot analysis. See Supplementary Table S1 for the list and sequences of primers used.

**Whole-mount histology and immunodetection.** Mice were induced with doxycycline at 9 wk of age, ovariectomized (OVX), and treated with  $E_2$  at 12 wk.  $E_2$  was administered as daily s.c. injections of sesame oil solution containing 1  $\mu$ g of  $E_2$ . Mammary glands from the MMTV/HEXIM1 mice were collected 25 d after start of  $E_2$  treatment for whole-mount staining via the Carmine-alum technique and Western blot analyses. Immunohistochemistry using sections from mammary glands are described in Supplementary data.

**Reverse transcription-PCR analyses.** Human breast epithelial cells, MCF-7, were maintained as described (19) and were transiently transfected with pCMV-TAG2B or pCMV-TAG2B-HEXIM1 using FuGENE HD reagent (Roche) according to the manufacturer's instructions. Forty-eight hours later, cells were treated with ethanol vehicle or 100 nmol/L  $E_2$  for 3 h. Total RNA was extracted using the TRIzol reagent (Invitrogen) and subjected to

reverse transcription-PCR (RT-PCR) analyses as described in Supplementary data.

**Western blot analyses.** Western blot analyses using extracts from mammary glands and MCF-7 cells are described in Supplementary data.

**RNA interference.** A Pol II promoter-driven miRNA expression vector system (Invitrogen) was used. To make pcDNA-HEXIM1 miR, miRNA oligos (see Supplementary Table S3 for list and sequences) were annealed and cloned into the pcDNA 6.2 GW/EmGFP vector (Invitrogen) according to the manufacturer's instructions. MCF-7 cells were transfected with pcDNA 6.2-GW/EmGFP-miR expression vectors containing either the HEXIM1 miRNA insert or a control LacZ miRNA insert. Following blasticidin selection, cells expressing the highest level of green fluorescent protein (GFP) were flow-sorted and expanded. During experiments, cells were treated with ethanol vehicle or 100 nmol/L  $E_2$  for 3 h and harvested as described above for Western blot analyses.

**Chromatin immunoprecipitation assays.** MCF-7 cells were plated on 150-mm plates and transfected as described with pCMV-TAG2B or pCMV-TAG2B-HEXIM1. Forty-eight hours later, cells were treated with ethanol vehicle or 100 nmol/L  $E_2$  for 45 and 90 min. Chromatin immunoprecipitation assays were carried out as previously described (19). See Supplementary data for further details of immunoprecipitation and analyses.


**CTD kinase assays.** Kinase assays were done according to previously described protocols with some modifications (23, 24). See Supplementary data for complete description of assay.

**Data analyses.** Statistical significance was determined using Student's *t* test comparison for unpaired data and was indicated as follows: \*,  $P < 0.05$ ; \*\*,  $P < 0.005$ .

## Results

**Increase in HEXIM1 expression inhibits  $E_2$ -driven mammary gland development by decreasing cell proliferation and increasing apoptosis.** To examine the functional consequences of an interaction between HEXIM1, ER $\alpha$ , and P-TEFb in the mammary gland, we generated a double transgenic mouse model, MMTV/HEXIM1, which inducibly overexpress HEXIM1 in the mammary gland when the mice are treated with doxycycline (+DOX). We first examined the effects of elevated levels of HEXIM1 on  $E_2$ -driven mammary gland development by having the MMTV/HEXIM1 mice ovariectomized and treated with  $E_2$  as described in Materials and Methods. In comparing whole mounts of mammary glands from -DOX and +DOX animal groups, we observed decreased ductal branching in the mammary glands of +DOX mice when compared with -DOX mice, as well as compared with single transgenics (MMTV alone; Fig. 1A, -DOX/+DOX, insets). We quantified the level of increase of HEXIM1 expression in the mammary gland as ~24% over endogenous levels (data not shown; see Fig. 2A for immunoblot), so we do not foresee that an overwhelming amount of HEXIM1 is needed to dictate these physiologic changes. Because ductal elongation and branching in the mammary gland have been shown to be  $E_2$ /ER $\alpha$  dependent (1, 25), these data suggest that HEXIM1 inhibits  $E_2$ /ER $\alpha$ -driven mammary gland morphogenesis.

Previously, we found that HEXIM1 inhibits ER $\alpha$  transcription (14, 19), so this physiologic effect could be due to a dysregulation of ER-responsive genes involved in proliferation and apoptosis. To investigate this, MMTV/HEXIM1 mice were injected with bromodeoxyuridine (BrdUrd) 2 hours before being sacrificed. BrdUrd-labeled nuclei in the mammary gland were detected by immunostaining and apoptotic nuclei were stained by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). Quantitation of positively labeled mouse mammary



**Figure 1.** Increased HEXIM1 expression inhibits estrogen-regulated mammary gland morphogenesis due to changes in proliferation and apoptosis. **A**, MMTV/HEXIM1 mice were treated as described in Materials and Methods. Representative whole mounts were obtained from MMTV and MMTV/HEXIM1 mice with Carmine alum stain. Original magnification,  $\times 40$ . OVX, ovariectomized. **B**, BrdUrd-labeled nuclei were detected by immunostaining and apoptotic nuclei were stained by TUNEL. Quantitation of positively labeled epithelial cell nuclei from at least 1,000 nuclei each from five mice per group (–DOX/+DOX). Original magnification,  $\times 40$ .

epithelial cell nuclei revealed both a decrease in epithelial cell proliferation and an increase in apoptosis (Fig. 1B). Taken together, our data suggest a critical role for HEXIM1 in E<sub>2</sub>/ER $\alpha$ -driven processes in the mammary gland.

**Increased HEXIM1 expression regulates cyclin D1 protein expression levels and serine 2 phosphorylation of RNAP II *in vivo*.** Our findings that overexpression of HEXIM1 decreased ductal branching and cell proliferation in the mammary gland prompted us to investigate the effect of HEXIM1 overexpression on E<sub>2</sub>/ER $\alpha$  signaling. As an output, we examined changes in cyclin D1 (CCND1) and c-Myc because both genes are E<sub>2</sub>/ER $\alpha$  responsive and involved in proliferation integral to mammary gland development and breast cancer (26, 27). MMTV/HEXIM1 mice were ovariectomized and treated with E<sub>2</sub> as described, and we found that increased HEXIM1 expression (+DOX) resulted in decreased CCND1 protein expression levels ( $\sim 67\%$ ) in mouse mammary gland cell extracts (Fig. 2A). However, c-Myc expression levels did not significantly change regardless of HEXIM1 expression (Supplementary Fig. S1A), suggesting a difference in sensitivity of ER $\alpha$  target genes to HEXIM1.

In addition, because HEXIM1 inhibits P-TEFb activity (12), we examined the effect of increased HEXIM1 expression on P-TEFb activity in the mouse mammary gland by investigating the expression levels of the S2P RNAP II. In +DOX mice, we observed a decrease in S2P RNAP II levels ( $\sim 68\%$ ; Fig. 2A). It is important to note here that the antibody used to detect S2P RNAP II recognizes both phosphorylated (RNAP II $\sigma$ ) and unphosphorylated (RNAP II $\alpha$ ) forms of RNAP II. We also blotted with another antibody that detects only the unphosphorylated form (Hypo RNAP II) and found that there was no observable change between –DOX and +DOX mice groups (Fig. 2A). In addition, HEXIM2, a paralogue of HEXIM1, inhibits P-TEFb activity (12), but in the mammary gland, HEXIM1 protein expression levels are significantly higher (Supplementary Fig. S1B), suggesting a dominant role for HEXIM1 in the mammary gland.


We also examined the expression levels of the serine 5 phosphorylated form of RNAP II (S5P RNAP II), associated with initiation, using immunofluorescent labeling of epithelial nuclei in mammary gland lumen from MMTV/HEXIM1 mice. We did not observe any changes in the percentage of S5P RNAP II positively stained nuclei (S5P +ve cells) when we compared –DOX and +DOX animal groups (Fig. 2B). However, in the +DOX animal group, the percentage of S2P RNAP II positively stained nuclei (S2P +ve cells) within the mammary gland lumen was significantly decreased by 50% ( $P < 0.05$ ) when compared with the –DOX group (Fig. 2B), verifying our results in the Western blot (Fig. 2A). Given that E<sub>2</sub>/ER $\alpha$  regulates CCND1 expression (21, 27) and HEXIM1 inhibits P-TEFb activity and associates with ER $\alpha$  (12, 19), the effect of increased HEXIM1 expression levels on CCND1 and S2P RNAP II expression suggests that these changes reflect a complex interaction of multiple pathways that converge at the level of E<sub>2</sub>/ER $\alpha$ -mediated transcription.

**HEXIM1 regulates cyclin D1 and pS2 expression levels *in vitro*.** The effects of increased HEXIM1 expression on CCND1 and S2P RNAP II expression levels could also be the sum result of the disruption of E<sub>2</sub>/ER $\alpha$  activity in multiple cell types in the mammary gland. To verify that our observations can be attributed to a more localized event in epithelial cells, we investigated the effects of increased HEXIM1 expression in mammary epithelial MCF-7 cells. MCF-7 cells were transfected with pCMV-Tag2B-HEXIM1 or control vector and treated with ethanol vehicle or E<sub>2</sub> for 3 hours. In control cells, we observed an average 1.5- to 2-fold E<sub>2</sub> induction of both CCND1 mRNA and protein levels (Fig. 3A and B), consistent with what has been shown in other studies (8, 21). As expected, increased HEXIM1 expression diminished E<sub>2</sub> induction of CCND1 mRNA and protein expression (Fig. 3A and B, compare lanes 2 and 4). For CCND1 protein expression levels, this was quantified as a 52% decrease in expression by HEXIM1 when normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression (Fig. 3B).


We also investigated the effect of increased HEXIM1 expression on other ER-responsive genes and found that increased HEXIM1 levels decreased  $E_2$ -induced increases in pS2 mRNA and protein levels (Fig. 3A and B; Supplementary Fig. S2A). The  $E_2$ -induced mRNA levels of other genes including c-Myc, progesterone receptor, and cathepsin D remained unchanged with increased HEXIM1 expression (Fig. 3A; Supplementary Fig. S2A). In addition,  $E_2$  induction of c-Myc protein levels was also unchanged with increased HEXIM1 expression (Fig. 3B, with quantitation in

Supplementary Fig. S2B). These data also suggest that increased HEXIM1 expression may not have a similar effect on all ER $\alpha$  target genes.

Having observed that increased HEXIM1 expression decreased  $E_2$ -induced CCND1 and pS2 expression, it stood to reason that HEXIM1 silencing would result in an increase in the induction of both genes by  $E_2$  when compared with control cells. HEXIM1 gene expression knockdown ( $\sim 50\%$ ) using miRNA-mediated RNA interference resulted in a statistically significant ( $P < 0.01$ )



**Figure 2.** Increased HEXIM1 expression inhibits  $E_2$ -induced cyclin D1 expression and serine 2 phosphorylation of RNAP II in mouse mammary gland. **A**, MMTV/HEXIM1 mice were treated as described in Materials and Methods. Mammary gland tissue extracts from MMTV/HEXIM1 mice were subjected to Western blot with indicated antibodies for immunoblotting. Anti-cytokeratin 18 was used as an epithelial cell marker and a loading control. RNAP II $\alpha$  and RNAP II $\beta$ , hypophosphorylated and hyperphosphorylated forms of RNAP II, respectively. Samples were collected from three to five mice per group (-DOX/+DOX) and columns represent quantitation of Western analyses for cyclin D1 and S2P RNAP II; bars, SE. \*,  $P < 0.01$ . **B**, immunofluorescent detection of S2P and S5P RNAP II. Representative images of mammary gland sections from MMTV/HEXIM1 mice (-DOX/+DOX) stained as described in Materials and Methods with S2P RNAP II- and S5P RNAP II-specific antibodies. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) as indicated. Original magnification,  $\times 20$ . Quantitation of S2P or S5P positively stained (S2P+ or S5P+) luminal epithelial cells was done as described in Materials and Methods. Columns, mean percentage of total S2P/S5P+ luminal epithelial cells with three to four mice per group (-DOX/+DOX) and a minimum of 1,000 cells per animal analyzed; bars, SE. \*,  $P < 0.05$ .



**Figure 3.** HEXIM1 regulates E<sub>2</sub>-induced cyclin D1 expression in breast epithelial cells. **A**, MCF-7 cells were transfected with pCMV-Tag2B-HEXIM1 or empty vector and treated with 100 nmol/L E<sub>2</sub> or ethanol vehicle for 3 h. RNA was extracted and subjected to RT-PCR as described in Materials and Methods. RT-PCR results quantitated for changes in cyclin D1 mRNA using GAPDH as a control. *Columns*, mean of four independent replicates; *bars*, SE. **B**, representative Western blot using indicated antibodies for immunoblotting. Changes in cyclin D1 protein levels were quantitated and normalized to GAPDH. *Columns*, mean of three independent replicates; *bars*, SE. \*, *P* < 0.05. **C**, representative Western blot indicating miRNA-mediated silencing of HEXIM1 in MCF-7 cells. E<sub>2</sub>-induced changes in cyclin D1 between LacZ and HEXIM1 miRNA stable cells were quantitated and normalized to GAPDH. *Columns*, mean of three independent replicates; *bars*, SE. \*, *P* < 0.01.


enhancement of E<sub>2</sub>-induced CCND1 protein expression levels (Fig. 3C). We did not observe a similar effect with pS2 (data not shown) and E<sub>2</sub>-induced c-Myc protein expression levels remained unchanged (Fig. 3C). Because multiple regulatory proteins are involved in CCND1 regulation (28), we cannot rule out possible actions of other factors *in vivo*. In addition, we cannot rule out the possibility of HEXIM1 regulation of other key E<sub>2</sub> responsive genes involved in cell proliferation and mammary carcinogenesis not studied here. Nonetheless, taken together, our data support a novel physiologic role for HEXIM1 in E<sub>2</sub>-driven mammary gland development via regulation of CCND1 levels and serine 2 phosphorylation of RNAP II.

**HEXIM1 inhibits E<sub>2</sub>-induced recruitment of ER $\alpha$  and cyclin T1 (P-TEFb) to ER $\alpha$ -responsive genes.** Given our observations on the effect of HEXIM1 expression on CCND1 and pS2, it is critical to characterize the molecular events involved in HEXIM1 transcriptional regulation of these ER-responsive genes. We previously reported that HEXIM1 associates with ER $\alpha$  after 90 minutes of E<sub>2</sub> stimulation in MCF-7 cells, and increased HEXIM1 expression led to a decrease in E<sub>2</sub>/ER $\alpha$  recruitment to the pS2 promoter (19). Other reports have shown that P-TEFb associates with the elongating form of RNAP II, S2P RNAP II, which is thought to predominate in the coding regions of genes with increased occupancy toward the 3' end of genes (29–31). Therefore, we


hypothesized that increased HEXIM1 levels would (a) inhibit the recruitment of ER $\alpha$  to the promoter region of ER target genes and (b) inhibit the recruitment of P-TEFb to regions downstream from the promoter at ER-responsive genes, and this would in turn verify the potential regulation of transcriptional elongation of these genes. To investigate this, we carried out chromatin immunoprecipitation assays in MCF-7 cells and examined the effect of E<sub>2</sub> on ER $\alpha$  and P-TEFb occupancy at two ER $\alpha$ -responsive genes, *pS2* and *CCND1*.

We found that an increase in HEXIM1 expression in MCF-7 cells correlated with a 2-fold increase in HEXIM1 occupancy at E<sub>2</sub>-

responsive regions within the *pS2* and *CCND1* (32) promoters (Supplementary Fig. S3A), which was not significantly affected by E<sub>2</sub> treatment. We also found that increased HEXIM1 expression inhibited the recruitment of E<sub>2</sub>/ER $\alpha$  to the promoter regions of *pS2* and *CCND1* (Fig. 4B). Now, it is well documented that E<sub>2</sub>/ER $\alpha$  cycles on and off the promoter of ER-responsive genes, and ER $\alpha$  binding is typically diminished after 90 minutes of E<sub>2</sub> stimulation (33, 34). Other studies have also shown that the absolute timing of ER $\alpha$  cycling differs and there can still be significant E<sub>2</sub>/ER $\alpha$  enrichment at 90 minutes (35, 36). In our studies, it is clear that E<sub>2</sub>/ER $\alpha$  binding is less at 90 minutes when compared with 45 minutes



**Figure 4.** Effect of increased HEXIM1 expression on E<sub>2</sub>-dependent recruitment of ER $\alpha$  and P-TEFb (cyclin T1) to ER-responsive genes. **A**, primers used in chromatin immunoprecipitation assays are directed at regions indicated for *pS2* and *CCND1* genes. **B**, increased HEXIM1 expression leads to decrease in E<sub>2</sub>/ER $\alpha$  recruitment to promoter regions of ER target genes, *pS2* and *CCND1*. Samples were prepared from MCF-7 cells transiently transfected with pCMV-Tag2B-HEXIM1 or empty vector, treated with ethanol vehicle or 100 nmol/L E<sub>2</sub> for 45 and 90 min. Chromatin immunoprecipitation was done with antibodies against ER $\alpha$  and rabbit IgG (as an immunoprecipitation control). **Left**, DNA fragments were analyzed by PCR with primers specific for the promoter-proximal region of *pS2* and *CCND1* as indicated in **A**. **Right**, quantifications of ER $\alpha$  immunoprecipitation enrichment at *pS2* and *CCND1* promoters. **Columns**, mean of two independent replicates; **bars**, SE. \*,  $P < 0.05$ ; \*\*,  $P < 0.005$ . **C**, HEXIM1 inhibits E<sub>2</sub>-dependent recruitment of cyclin T1 to coding regions of *pS2* and *CCND1*. MCF-7 cells were treated as described in **B**. Chromatin immunoprecipitation analysis of cyclin T1 recruitment to E<sub>2</sub>-responsive region of *pS2* and *CCND1* promoter and coding regions was carried out using primers specific for the regions indicated in **A**. **Left**, DNA fragments were analyzed by PCR with primers specific for the regions indicated. **Right**, quantifications of cyclin T1 immunoprecipitation enrichment at *pS2* gene. **Columns**, mean of two to three independent replicates; **bars**, SE. \*,  $P < 0.05$ .



**Figure 5.** Increased HEXIM1 expression inhibits E<sub>2</sub>-induced P-TEFb activity and recruitment of serine 2 (hyperphosphorylated) RNAP II to the coding region of ER-responsive genes. **A**, increased HEXIM1 expression decreased E<sub>2</sub>-induced CTD4 peptide phosphorylation. MCF-7 cells were transiently transfected with pCMV-Tag2B-HEXIM1 or empty vector and treated with ethanol vehicle or 100 nM E<sub>2</sub> for 90 min. Cell lysates were subjected to immunoprecipitation with antibodies against cyclin T1 and rabbit IgG (as an immunoprecipitation control). The immunoprecipitates were divided into two halves with one half getting 2 μg of the CTD4 peptide added to the reaction (-CTD4/+CTD4). DRB at 50 μM/L was also added to some immunoprecipitates as a kinase assay control. The kinase reactions were analyzed by SDS-PAGE using autoradiography. Equal volumes of kinase reactions were also analyzed by Western blot to check specificity of anti-cyclin T1 antibody in immunoprecipitation. Representative of at least four independent experiments. **B**, HEXIM1 inhibits E<sub>2</sub>-dependent recruitment of S2P RNAP II to pS2 ORF. MCF-7 cells were treated as described in Fig. 4 and subjected to chromatin immunoprecipitation analysis with antibodies against S2P RNAP II, S5P RNAP II, and the unphosphorylated form of RNAP II (8WG16). The regions of pS2 amplified by PCR are as indicated. Columns, mean of three to five independent replicates; bars, SE. \*\*,  $P < 0.005$ . **C**, HEXIM1 inhibits E<sub>2</sub>-dependent recruitment of S2P RNAP II to CCND1 ORF. MCF-7 cells were treated as described. The regions of CCND1 amplified by PCR are as indicated. Columns, mean of three to four independent replicates; bars, SE. \*,  $P < 0.05$ .

(Fig. 4B, compare lanes 2 and 3), and we see a significant decrease at 3 hours (data not shown), indicating that E<sub>2</sub>/ERα is cycling on DNA in our experiments. Regardless of the time point of E<sub>2</sub> stimulation, increased HEXIM1 inhibits E<sub>2</sub>/ERα recruitment to DNA.

For P-TEFb (via cyclin T1), we observed an E<sub>2</sub>-dependent recruitment pattern that differed slightly at the promoter and coding regions of both pS2 and CCND1 genes. At the promoters of both pS2 and CCND1, cyclin T1 follows a similar trajectory as ERα in terms of recruitment in control cells, but there is no significant effect on cyclin T1 recruitment with increased HEXIM1 expression (Fig. 4C). However, at the coding regions of both genes,

we observed a gradual increase in cyclin T1 recruitment over time with E<sub>2</sub> stimulation, and increased HEXIM1 expression inhibited the recruitment of cyclin T1 (Fig. 4C). As a further control, we looked at cyclin T1 recruitment to the GAPDH open reading frame (ORF) at a region that has been shown to have significant RNAP II enrichment during GAPDH transcription (37). We did not observe an E<sub>2</sub>-dependent recruitment pattern and there were no significant changes in cyclin T1 recruitment with increased HEXIM1 expression (Supplementary Fig. S3B).

These data suggest that HEXIM1 inhibits ERα transcriptional elongation by inhibiting P-TEFb recruitment, via cyclin T1, to the coding region of some ER-responsive genes. This result is

consistent with other studies showing that the recruitment of P-TEFb to promoter-proximal and coding regions stimulates transcriptional elongation (30, 38). In addition, in previous studies, we observed a decrease in the co-recruitment of cyclin T1 with ER $\alpha$  at the *pS2* promoter with increased HEXIM1 expression (19), but it seems that the total occupancy of cyclin T1 at the promoter region does not change with increased HEXIM1 expression (Fig. 4C). In this context, our data suggest a dual role for P-TEFb in ER $\alpha$  transcription. On one hand, it acts as a coactivator for ER $\alpha$ -driven transcription by directly associating with E<sub>2</sub>/ER $\alpha$  (19), but it also serves its general purpose as a transcription elongation factor, with E<sub>2</sub> acting as an enhancer of P-TEFb occupancy in the context of ER-responsive genes.

**HEXIM1 inhibits E<sub>2</sub>-induced P-TEFb activity and recruitment of S2P RNAP II to coding regions of ER-responsive genes.** Because E<sub>2</sub> enhanced P-TEFb recruitment to *pS2* and *CCND1* genes, we investigated if E<sub>2</sub> also increased P-TEFb activity as a means of promoting transcriptional elongation of ER $\alpha$ -responsive genes. To do this, we conducted kinase assays using endogenous immunoprecipitates of cyclin T1 from MCF-7 cells and examined the kinase activity of P-TEFb with a synthetic peptide substrate, CTD4 (YSPTSPS<sub>4</sub>). As shown in Fig. 5A, E<sub>2</sub> treatment increased P-TEFb activity in MCF-7 cells (compare lanes 2 and 5). We also observed that increased HEXIM1 expression in MCF-7 cells inhibited E<sub>2</sub>-induced increase in P-TEFb activity (Fig. 5A, compare lanes 2 and 5 with lanes 8 and 11). We confirmed that this inhibition was selective for P-TEFb by adding the CDK9 inhibitor DRB to an equal half of the kinase immunoprecipitates (Fig. 5A, lanes 3, 6, 9, and 12) and that the input levels of cyclin T1 and HEXIM1 were evenly loaded (Supplementary Fig. S4A). Quantitation of <sup>32</sup>P incorporation into the CTD4 peptide verified that HEXIM1 significantly abrogates E<sub>2</sub>-induced P-TEFb activity in MCF-7 cells (Supplementary Fig. S4B).


We also observed that increased HEXIM1 expression did not inhibit basal P-TEFb activity in HEXIM1-transfected MCF-7 cells compared with nontransfected cells (Fig. 5A, compare lanes 2 and 8). One reason for this could be attributed to the fact that at basal levels, the P-TEFb complex is thought to occur in two states, 50% free and 50% HEXIM1-7SK RNA bound (12), and in a study by He and colleagues (11), gradually decreasing HEXIM1 expression by RNA interference did not initially have much effect on this equilibrium because it was the “free” form of HEXIM1 that was being down-regulated, without any effect on the HEXIM1 protein associated with P-TEFb. In our experiments, it is possible that increasing HEXIM1 expression may not be significantly perturbing the P-TEFb equilibrium initially, but increases the availability of free HEXIM1 populations, which subsequently diminishes any increases in E<sub>2</sub>-induced P-TEFb activity.

Because HEXIM1 inhibited the recruitment of cyclin T1 to the coding regions of ER-responsive genes and E<sub>2</sub>-induced P-TEFb activity, we determined the effect of increased HEXIM1 levels on the recruitment of S2P RNAP II as a mark of the modulation of transcription elongation (9). At the *pS2* promoter, we found that E<sub>2</sub> stimulated the enrichment of all forms of RNAP II, without any significant changes when HEXIM1 expression was increased (Fig. 5B). This result differs from what has been observed in some studies, which show low S2P RNAP II occupancy in comparison with S5P RNAP II at the promoter of transcriptionally active genes (29, 37). However, it is possible for both S2P and S5P RNAP II to occupy similar regions on DNA (39), which likely marks the beginning of the transition to elongation, but it is unclear because we did not study proximal upstream or downstream regions to the *pS2* promoter. In addition, there was no change in the recruitment of all forms of RNAP II to the *CCND1* promoter in both control and HEXIM1-transfected cells, although it was not as sensitive as the *pS2* promoter to E<sub>2</sub> stimulation (Fig. 5C).

However, at the *pS2* and *CCND1* coding regions, we found that increased HEXIM1 expression inhibited the E<sub>2</sub>-dependent recruitment of S2P RNAP II, without significant changes in the recruitment of S5P and unphosphorylated RNAP II forms (Fig. 5B and C). These data indicate that in mammary epithelial cells, HEXIM1 does not affect transcription initiation because the recruitment patterns of all forms of RNAP II to the promoter regions of *pS2* and *CCND1* were unchanged regardless of HEXIM1 expression levels in the cell. However, increased HEXIM1 decreases transcription elongation because the recruitment of S2P RNAP II to the coding region was decreased.

## Discussion

This study provides novel evidence for a physiologic role of HEXIM1/P-TEFb interaction in attenuating E<sub>2</sub>/ER $\alpha$  driven transcription in the mammary gland and breast cancer cells. First, we showed that increased HEXIM1 expression in the mammary gland of a transgenic mouse model decreased ductal branching, an E<sub>2</sub>-driven developmental process, due to changes in proliferation and apoptosis. We correlated these changes with a decrease in *CCND1* and S2P RNAP II expression *in vivo* and *in vitro*. We also show that overexpression of HEXIM1 diminished E<sub>2</sub>-induced recruitment of ER $\alpha$  and cyclin T1 to the promoter and coding regions, respectively, of ER-responsive genes. Further, we show that E<sub>2</sub> enhances the activity of the P-TEFb kinase CDK9, which is inhibited by increased HEXIM1 expression. Surprisingly, increased HEXIM1 expression inhibited only E<sub>2</sub>-induced increases in P-TEFb activity and not basal P-TEFb kinase activity. In our studies, this



**Figure 6.** Proposed model for HEXIM1 action on ER $\alpha$  and P-TEFb at ER-responsive genes *pS2* and *CCND1* in mammary cells.

inhibition of P-TEFb activity translates to a decrease in the recruitment of S2P RNAP II, and not other forms of RNAP II, to the coding regions of the ER-responsive genes *pS2* and *CCND1*. These findings support a role for P-TEFb and transcription elongation in cell proliferation, but more importantly, the data suggest a novel mechanism of action for HEXIM1 that can be recapitulated *in vivo* and a possible therapeutic role for HEXIM1 in hormone-dependent breast cancer.

Given that the regulation of *CCND1* is complex (28), we do not assume that our findings represent a comprehensive explanation about E<sub>2</sub>-regulation of *CCND1*. In addition, other sites within *CCND1* contribute to the transcriptional output (21). We investigated the recruitment patterns of ER $\alpha$ , P-TEFb, and RNAP II to two sites within the gene: an E<sub>2</sub>-responsive region of the promoter and the coding region. Perhaps, a more extensive analysis of different sites within the genes *pS2* and *CCND1* and even other ER-responsive genes will reveal other insights into the mechanism of HEXIM1 regulation of these genes. However, we believe that the information gathered from this study was sufficient to show the regulatory effects of HEXIM1 on ER $\alpha$  and P-TEFb recruitment to *pS2* and *CCND1*, suggesting a role for HEXIM1 and P-TEFb in ER $\alpha$  transcriptional regulation of some, but not all, ER $\alpha$  target genes.

Based on our previous (19) and current studies, we speculate that E<sub>2</sub> enhances an ER $\alpha$ -P-TEFb interaction, and this increases the population of active P-TEFb at the gene locus of ER-responsive genes, which in turn phosphorylates the CTD of RNAP II. This phosphorylation event positions the gene in an active elongation state with increased S2P RNAP II occupancy at the coding regions and enhanced recruitment of other forms of RNAP II marking the gene in an active transcription state (31, 39). However, increased HEXIM1 expression inhibits ER $\alpha$  and P-TEFb enrichment at the promoter and coding regions, respectively, of ER-responsive genes, thus decreasing the population of P-TEFb available to phosphorylate RNAP II to the serine 2 phosphorylated form associated with transcriptional elongation. In addition, we observed that increased HEXIM1 inhibits E<sub>2</sub>-induced P-TEFb activity and postulated that this was due to an increase in the "free" form of HEXIM1, which serves to diminish any subsequent increases in P-TEFb activity. Taken together, this scenario could represent the mechanism by which HEXIM1 modulates ER $\alpha$ -mediated transcription in the context of some ER-responsive genes (see Fig. 6 for proposed model).

The understanding of general mechanisms that control elongation stems from studies showing that HIV-1 harnesses P-TEFb as a cofactor to promote efficient mRNA transcript synthesis (12). These and other studies have raised questions about whether P-TEFb acts as a general transcription elongation factor or serves in a gene-selective or context-dependent manner. The P-TEFb complex components, cyclin T1 and CDK9, have not been shown to have sequence-specific DNA binding activity, but transcription factors interact with and recruit P-TEFb to their respective promoter targets (12, 40, 41). In addition, DNA microarray analyses of hearts from cyclin T1 transgenic mice indicate selective

increases in subsets of genes, rather than a global increase in mRNA expression, when compared with nontransgenic mice (42). Our studies suggest that in breast epithelial cells, P-TEFb can be modulated by E<sub>2</sub>/ER $\alpha$  and HEXIM1 in the context of some ER $\alpha$  target genes, although identical E<sub>2</sub>-induced recruitment patterns for P-TEFb to *pS2* and *CCND1* genes suggest that a general transcription elongation mechanism is also involved. In addition, the interaction of P-TEFb and E<sub>2</sub>/ER $\alpha$  supports a positive aspect of ER $\alpha$  transcription elongation regulation, but E<sub>2</sub>/ER $\alpha$  also interacts with negative elongation factor (NELF) and this interaction inhibits ER $\alpha$ -mediated transcription (43).

HEXIM1 has been shown to have P-TEFb-independent action as seen with the glucocorticoid receptor (44). We have also reported on P-TEFb-independent action of HEXIM1 in cardiovascular development (45). Given this evidence, it is clear that HEXIM1 can inhibit transcription in a P-TEFb-dependent and P-TEFb-independent manner. Therefore, we cannot assume that the effect of HEXIM1 in the mammary gland is solely on ER $\alpha$ /P-TEFb because other factors are involved in mammary gland development. However, we were able to show a specific inhibition pattern that HEXIM1 exerted on E<sub>2</sub>-induced events at ER-responsive genes, *pS2* and *CCND1*, and increased HEXIM1 levels inhibited E<sub>2</sub>-induced P-TEFb activity. Thus, based on our data, the HEXIM1 inhibition patterns observed in this study are largely P-TEFb dependent in both our cell culture and animal models. Several studies also support an emerging role for HEXIM1 as a regulator of cell growth and differentiation (12, 46). Conversely, deletion of *CLP-1*, the mouse HEXIM1 gene, leads to pathologic cardiac hypertrophy and perinatal death (47).

In this study, a targeted increase in HEXIM1 expression in the mouse mammary gland driven by a mammary epithelial cell promoter (MMTV-LTR) led to a decrease in ductal branching (Fig. 1A), an E<sub>2</sub>/ER $\alpha$ -driven mammary gland developmental process (25). This observation was attributed to a decrease in proliferation and an increase in apoptosis (Fig. 1B). The decrease in proliferation was linked to a concurrent decrease in *CCND1* expression, further showing that HEXIM1 regulates ER-responsive genes *in vivo*. Future studies will aim to address not only HEXIM1 regulation of other E<sub>2</sub>/ER $\alpha$  target genes but also HEXIM1 regulation of other nuclear receptors relevant in mammary cell function and tumorigenesis.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

Received 3/3/2008; revised 6/24/2008; accepted 6/26/2008.

**Grant support:** NIH grant CA92440 (M.M. Montano) and Department of Defense Predoctoral Fellowship W81XWH-06-1-0426 (N. Ogba).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Huayun Deng for his help with some of the animal work and advice on immunohistochemistry, and Dr. Lewis Chodosh (University of Pennsylvania) for the MTB mice and the pTet-Splice vector.

## References

- Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. *J Mammary Gland Biol Neoplasia* 1997;2:323-34.
- Faulds MH, Olsen H, Helguero LA, Gustafsson JA, Haldosen LA. Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. *Mol Endocrinol* 2004;18:412-21.
- Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ER $\beta$  expression as a common step in

- estrogen-dependent tumor progression. *Endocr Relat Cancer* 2004;11:537–51.
4. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. *Annu Rev Physiol* 2005;67:285–308.
  5. Deroo BJ, Korach KS. Estrogen receptors and human disease. *J Clin Invest* 2006;116:561–70.
  6. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. *J Steroid Biochem Mol Biol* 2000;74:311–7.
  7. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. *N Engl J Med* 2006;354:270–82.
  8. Cheng AS, Jin VX, Fan M, et al. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor- $\alpha$  responsive promoters. *Mol Cell* 2006;21:393–404.
  9. Sims RJ III, Belotserkovskaya R, Reinberg D. Elongation by RNA polymerase II: the short and long of it. *Genes Dev* 2004;18:2437–68.
  10. Svestrup JQ. The RNA polymerase II transcription cycle: cycling through chromatin. *Biochim Biophys Acta* 2004;1677:64–73.
  11. He N, Pezda AC, Zhou Q. Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. *Mol Cell Biol* 2006;26:7068–76.
  12. Zhou Q, Yik JH. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. *Microbiol Mol Biol Rev* 2006;70:646–59.
  13. Garriga J, Grana X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. *Gene* 2004;337:15–23.
  14. Wittmann BM, Wang N, Montano MM. Identification of a novel inhibitor of breast cell growth that is down-regulated by estrogens and decreased in breast tumors. *Cancer Res* 2003;63:5151–8.
  15. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of P-TEFb (CDK9/cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. *Mol Cell* 2003;12:971–82.
  16. Michels AA, Fraldi A, Li Q, et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. *EMBO J* 2004;23:2608–19.
  17. Byers SA, Price JP, Cooper JJ, Li Q, Price DH. HEXIM2, a HEXIM1-related protein, regulates positive transcription elongation factor b through association with 7SK. *J Biol Chem* 2005;280:16360–7.
  18. Yik JH, Chen R, Pezda AC, Zhou Q. Compensatory contributions of HEXIM1 and HEXIM2 in maintaining the balance of active and inactive positive transcription elongation factor b complexes for control of transcription. *J Biol Chem* 2005;280:16368–76.
  19. Wittmann BM, Fujinaga K, Deng H, Ogba N, Montano MM. The breast cell growth inhibitor, estrogen down-regulated gene 1, modulates a novel functional interaction between estrogen receptor  $\alpha$  and transcriptional elongation factor cyclin T1. *Oncogene* 2005;24:5576–88.
  20. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G<sub>1</sub>. *Genes Dev* 1993;7:812–21.
  21. Eeckhoutte J, Carroll JS, Geistlinger TR, Torres-Arzuayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. *Genes Dev* 2006;20:2513–26.
  22. Gunther EJ, Belka GK, Wertheim GB, et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. *FASEB J* 2002;16:283–92.
  23. Kershner E, Wu SY, Chiang CM. Immunoaffinity purification and functional characterization of human transcription factor IIH and RNA polymerase II from clonal cell lines that conditionally express epitope-tagged subunits of the multiprotein complexes. *J Biol Chem* 1998;273:34444–53.
  24. Fraldi A, Varrone F, Napolitano G, et al. Inhibition of Tat activity by the HEXIM1 protein. *Retrovirology* 2005;2:42.
  25. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. *Physiol Rev* 2007;87:905–31.
  26. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. *J Clin Oncol* 2005;23:4215–24.
  27. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. *Endocr Relat Cancer* 2005;12 Suppl:647–59.
  28. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. *Endocrinology* 2004;145:5439–47.
  29. Komarnitsky P, Cho E, Buratowski S. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. *Genes Dev* 2000;14:2452–60.
  30. Cho E, Kobor MS, Kim M, Greenblatt J, Buratowski S. Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain. *Genes Dev* 2001;15:3319–29.
  31. Ahn SH, Kim M, Buratowski S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3' end processing. *Mol Cell* 2004;13:67–76.
  32. Cicatiello L, Addeo R, Sasso A, et al. Estrogens and progesterone promote persistent CCND1 gene activation during G<sub>1</sub> by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. *Mol Cell Biol* 2004;24:7260–74.
  33. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 2000;103:843–52.
  34. Métévier R, Penot G, Hübner MR, et al. Estrogen receptor  $\alpha$  directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. *Cell* 2003;115:751–63.
  35. Burakov D, Crofts LA, Chang CB, Freedman LP. Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes *in vivo* by estrogen receptor. *J Biol Chem* 2002;277:14359–62.
  36. Shao W, Krasnikas E, McDonnell DP, Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. *Proc Natl Acad Sci U S A* 2004;101:11599–604.
  37. Morris DP, Michelotti GA, Schwinn DA. Evidence that phosphorylation of the RNA polymerase II carboxy-terminal repeats is similar in yeast and humans. *J Biol Chem* 2005;280:31368–77.
  38. Contreras X, Barboric M, Lenasi T, Peterlin BM. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. *PLoS Pathog* 2007;3:e146.
  39. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Epinosa JM. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. *Genes Dev* 2006;20:601–12.
  40. Iankova I, Petersen RK, Annicotte JS, et al. Peroxisome proliferator-activated receptor  $\gamma$  recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. *Mol Endocrinol* 2006;20:1494–505.
  41. Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. *Oncogene* 2003;22:5707–11.
  42. Sano M, Abdellatif M, Oh H, et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. *Nat Med* 2002;8:1310–7.
  43. Aiyar SE, Sun J, Blair AL, et al. Attenuation of estrogen receptor  $\alpha$ -mediated transcription through estrogen-stimulated recruitment of a negative elongation factor. *Genes Dev* 2004;18:2134–46.
  44. Shimizu N, Ouchida R, Yoshikawa N, et al. HEXIM1 forms a transcriptionally abortive complex with glucocorticoid receptor without involving 7SK RNA and positive transcription elongation factor b. *Proc Natl Acad Sci U S A* 2005;102:8555–60.
  45. Montano MM, Doughman YQ, Deng H, et al. Mutation of the HEXIM1 gene results in defects during heart and vascular development partly through down-regulation of vascular endothelial growth factor. *Circ Res* 2008;102:415–22.
  46. Turano M, Napolitano G, Dulac C, Majello B, Bensaude O, Lania L. Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation. *J Cell Physiol* 2006;206:603–10.
  47. Huang F, Wagner M, Siddiqui MA. Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. *Mech Dev* 2004;121:559–72.